TRU-015: Preliminary Phase IIb data

Preliminary data from double-blind Phase IIb trial in 276 RA patients showed that 1 of 4 TRU-015 doses (800 mg) met the primary endpoint of a significant improvement in DAS-28 scale at 12 weeks vs. pl...